10 completed, 2 terminated. 8 Phase 1, 4 Phase 2, 1 Phase 3.
By phase and status
Follow AZD4831: new trials by email Literature Review of AZD4831 trials Research Report on AZD4831
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
Mitiperstat - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 31 | 2023-03-20 | 2024-12-05 |
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Mitiperstat (AZD4831), Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 381 | 2022-11-14 | 2025-08-29 |
A Study in Participants With Non-cirrhotic NASH With Fibrosis
AZD4831, Placebo - Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | Phase 2 | Completed | AstraZeneca | 112 | 2022-10-26 | 2025-07-09 |
A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
AZD4831 - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 30 | 2022-08-11 | 2022-11-01 |
A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
AZD4831, Itraconazole - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 21 | 2022-02-18 | 2022-08-23 |
A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
AZD4831 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 20 | 2022-01-21 | 2022-04-05 |
Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam
AZD4831, Midazolam - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 14 | 2021-10-05 | 2021-12-13 |
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
AZD4831, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 / Phase 3 | Completed | AstraZeneca | 711 | 2021-06-30 | 2025-08-27 |
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
AZD4831, Placebo - Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 1 | Completed | AstraZeneca | 32 | 2020-01-16 | 2021-04-01 |
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
AZD4831, Placebo - Heart Failure | Phase 2 | Terminated | AstraZeneca | 41 | 2018-12-11 | 2021-07-19 |
A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease
AZD4831, Placebo - Cardiovascular Disease | Phase 1 | Completed | AstraZeneca | 38 | 2017-05-15 | 2020-01-18 |
A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects
AZD4831, AZD4831 placebo - Cardiovascular Disease | Phase 1 | Terminated | AstraZeneca | 104 | 2016-06-01 | 2017-01-06 |
Conditions studied
Cardiovascular Diseases (5) · Heart Failure (2) · Fatty Liver (1) · Liver Diseases (1) · Pulmonary Disease, Chronic Obstructive (1) · Renal Insufficiency (1)
Sponsors
AstraZeneca (12)
Countries
United States (8) · Denmark (4) · Bulgaria (3) · Netherlands (3) · Sweden (3) · United Kingdom (3) · Argentina (2) · Canada (2) · Italy (2) · Mexico (2) · Poland (2) · Spain (2) · Turkey (Türkiye) (2) · Australia (1) · Belgium (1)
Top investigators
David Han, M.D (1) · David Han, MD (1) · Rainard Fuhr, Dr. med. (1)
Results publications
PMID 37072105, PMID 37470101, PMID 39495467, PMID 41108609, PMID 42101107, PMID 42276801, PMID 42661940, PMID 42717033